News Bayer's regorafenib kicks off brain cancer platform trial Bayer has become the first pharma company to take part in a new platform trial designed to find new treatments for brain cancer.
News BMS’ Opdivo fails late-stage brain cancer test Bristol-Myers Squibb has run into yet another hurdle trying to extend the use of its immuno-oncology blockbuster Opdivo into new types of cancer.
Views & Analysis An echo through brain cancer’s empty pipeline Brain tumours kill more people aged under 40 than any other cancer, yet there have been no new treatments for more than a decade. What’s more, there are still none in the pipeline.
News Certain brain tumours could respond to immunotherapy Some brain tumours may respond to immunotherapy after all, according to a new study.
Views & Analysis Kick-starting innovation in Glioblastoma Can risk-sharing and real-world evidence can provide traction in treating the brain cancer Glioblastoma?
Oncology In pursuit of a cure for cancer: An ASCO 2025 discussion wit... Dr Danny Nguyen, medical oncologist and haematologist at the City of Hope Orange County, spoke with pharmaphorum at ASCO 2025.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face